BR9809342A - Composto, composição farmacêutica, e, uso do composto - Google Patents

Composto, composição farmacêutica, e, uso do composto

Info

Publication number
BR9809342A
BR9809342A BR9809342-8A BR9809342A BR9809342A BR 9809342 A BR9809342 A BR 9809342A BR 9809342 A BR9809342 A BR 9809342A BR 9809342 A BR9809342 A BR 9809342A
Authority
BR
Brazil
Prior art keywords
compound
amino acid
pharmaceutical composition
tiq
piq
Prior art date
Application number
BR9809342-8A
Other languages
English (en)
Inventor
Anton Egbert Peter Adang
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR9809342A publication Critical patent/BR9809342A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, USO DO COMPOSTO" A invenção diz respeito a um composto tendo a fórmula (I) R^ 1^SO~ 2~-B-X-Z-C-(O)-Y B é uma ligação, um aminoácido da fórmula -NH-CH[(CH~ 2~)~ p~C(O)OH]-C(O)- ou um seu derivado éster, em que p é 1, 2 ou 3, Gly, D-1-Piq, D-3-Piq, D-1-Tiq, D-3-Tiq. D-Atc. Aic ou um aminoácido L ou D tendo uma cadeia lateral hidrofóbica, básica ou neutra; X é um aminoácido com uma cadeia lateral hidrofóbica, glutamina, serina, treonina, um aminoácido cíclico opcionalmente contendo um heteroátomo adicional selecionado de N, O ou S, e opcionalmente substituído por alquila (1-6C), alcóxi (1-6C), benzilóxi ou oxo, ou X é ácido 2-amino-isobutírico, -NR^ 2^-CH~ 2~-C(O)- ou o fragmento (I) em que n é 2, 3 ou 4, W é CH ou N, e R^ 3^ é H, alquila (1-6C) ou fenila, cujos grupos podem opcionalmente ser substituídos por hidróxi, alcóxi (1-6C), COOH, COOalquila (1-6C), CONH~ 2~ ou halogênio; Z é lisina ou 4-aminociclo-hexilglicina. Os compostos da invenção têm atividade anticoagulante e podem ser usados no tratamento ou prevenção de doenças relacionadas com a trombina. A variável R^ 1^ e Y são definidos na reivindicação 1.
BR9809342-8A 1997-05-02 1998-04-28 Composto, composição farmacêutica, e, uso do composto BR9809342A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97201286 1997-05-02
PCT/EP1998/002587 WO1998050420A1 (en) 1997-05-02 1998-04-28 Serine protease inhibitors

Publications (1)

Publication Number Publication Date
BR9809342A true BR9809342A (pt) 2000-07-04

Family

ID=8228278

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809342-8A BR9809342A (pt) 1997-05-02 1998-04-28 Composto, composição farmacêutica, e, uso do composto

Country Status (23)

Country Link
US (1) US6534495B1 (pt)
EP (1) EP0979240B1 (pt)
JP (1) JP2001524117A (pt)
KR (1) KR20010012174A (pt)
CN (1) CN1254345A (pt)
AR (1) AR012631A1 (pt)
AT (1) ATE264339T1 (pt)
AU (1) AU729910B2 (pt)
BR (1) BR9809342A (pt)
CA (1) CA2287569A1 (pt)
DE (1) DE69823178T2 (pt)
DK (1) DK0979240T3 (pt)
ES (1) ES2218827T3 (pt)
HU (1) HUP0002942A3 (pt)
ID (1) ID22904A (pt)
NO (1) NO995316D0 (pt)
NZ (1) NZ500620A (pt)
PL (1) PL336589A1 (pt)
PT (1) PT979240E (pt)
RU (2) RU2183642C2 (pt)
TR (1) TR199902692T2 (pt)
WO (1) WO1998050420A1 (pt)
ZA (1) ZA983629B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900043D0 (sv) * 1999-01-11 1999-01-11 Astra Ab New use
BR9916732A (pt) 1999-01-02 2001-09-25 Aventis Pharma Gmbh Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa)
US6344450B1 (en) * 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
AU3731400A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
RU2255933C9 (ru) * 1999-05-07 2005-11-20 Тексэс Байотекнолоджи Копэрейшн ПРОИЗВОДНЫЕ ПРОПИОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ СЕЛЕКТИВНОГО ИНГИБИРОВАНИЯ СВЯЗЫВАНИЯ α4β1 ИНТЕГРИНА
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
JP2000344739A (ja) 1999-06-01 2000-12-12 Sumitomo Chem Co Ltd Ｎ−保護−アゼチジン−２−カルボン酸の製造方法
AU2055301A (en) * 1999-12-03 2001-06-12 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
EP1127884A1 (en) * 2000-02-26 2001-08-29 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them
US6660885B2 (en) 2000-03-13 2003-12-09 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
JP2004505013A (ja) 2000-04-05 2004-02-19 ファルマシア・コーポレーション 凝固カスケードを選択的に阻害するのに有用な多環式アリール及びヘテロアリール置換４−ピリドン類
EP1268463B1 (en) 2000-04-05 2005-02-16 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
JP2004501077A (ja) 2000-04-17 2004-01-15 ファルマシア・コーポレーション 凝固カスケードの選択的阻害に有用な多環式アリールおよびヘテロアリール置換１，４−キノン
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
MXPA03004458A (es) 2000-11-20 2005-01-25 Pharmacia Corp Arilpiridinas y heteroarilpiridinas sustituidas utiles para inhibicion selectiva de la cascada de coagulacion.
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
EP1358178A2 (en) 2001-01-30 2003-11-05 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
GB0119370D0 (en) * 2001-08-08 2001-10-03 Univ London Therapeutic agent
ATE361068T1 (de) 2001-08-08 2007-05-15 Pentraxin Therapeutics Ltd Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma
WO2003029216A1 (en) 2001-10-03 2003-04-10 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
WO2003093242A2 (en) 2001-10-03 2003-11-13 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease
WO2005019434A2 (en) 2003-08-26 2005-03-03 The Regents Of The University Of Colorado, A Body Corporate Serine protease inhibitors for treatment of bacterial infections
WO2007137080A2 (en) 2006-05-23 2007-11-29 Irm Llc Compounds and compositions as channel activating protease inhibitors
MX2009008518A (es) 2007-02-09 2009-08-20 Irm Llc Compuestos y composiciones como inhibidores de la proteasa activadora de canal.
WO2010103475A2 (en) 2009-03-10 2010-09-16 Med Discovery Sa Use of serine protease inhibitors in the treatment of neutropenia
AU2019242595A1 (en) * 2018-03-28 2020-11-19 Blade Therapeutics, Inc. Method of treating fibrotic disease
DE102020103516B4 (de) 2020-02-11 2023-12-07 Universität Zu Lübeck Antivirale Wirkstoffe mit breiter Aktivität

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600226B2 (en) * 1985-02-04 1990-08-09 Merrell Pharmaceuticals Inc. Novel peptidase inhibitors
US5919765A (en) 1995-06-07 1999-07-06 Cor Therapeutics, Inc. Inhibitors of factor XA
IL119466A (en) * 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
WO1998009987A1 (en) * 1996-09-06 1998-03-12 Biochem Pharma, Inc. Lactam inhibitors of thrombin

Also Published As

Publication number Publication date
WO1998050420A1 (en) 1998-11-12
ES2218827T3 (es) 2004-11-16
EP0979240A1 (en) 2000-02-16
AU729910B2 (en) 2001-02-15
ID22904A (id) 1999-12-16
DK0979240T3 (da) 2004-07-26
HUP0002942A3 (en) 2001-12-28
JP2001524117A (ja) 2001-11-27
DE69823178D1 (de) 2004-05-19
ATE264339T1 (de) 2004-04-15
TR199902692T2 (xx) 2000-07-21
KR20010012174A (ko) 2001-02-15
PT979240E (pt) 2004-08-31
NO995316L (no) 1999-11-01
NZ500620A (en) 2000-10-27
CA2287569A1 (en) 1998-11-12
HUP0002942A2 (hu) 2001-01-29
EP0979240B1 (en) 2004-04-14
CN1254345A (zh) 2000-05-24
NO995316D0 (no) 1999-11-01
DE69823178T2 (de) 2005-06-23
US6534495B1 (en) 2003-03-18
AR012631A1 (es) 2000-11-08
PL336589A1 (en) 2000-07-03
RU2002104026A (ru) 2004-04-27
RU2183642C2 (ru) 2002-06-20
AU7652098A (en) 1998-11-27
ZA983629B (en) 1998-11-04

Similar Documents

Publication Publication Date Title
BR9809342A (pt) Composto, composição farmacêutica, e, uso do composto
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
YU56995A (sh) Soli derivata indola
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
BR0212455A (pt) Composto, formulação farmacêutica, combinação, uso de um composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, e, processo para preparar um composto
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
BR0315720A (pt) Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
IS4695A (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
ES2096614T3 (es) Derivados de acidos biliares, procedimiento para su preparacion y utilizacion de este compuesto como medicamento.
NZ210275A (en) Modified hirudin and its antithrombin properties
BR9812095A (pt) Compostos de indol como inibidores de cox-2
BR9810312A (pt) Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
BR0015939A (pt) Sistemas terapêuticos transdérmicos com estabilidade aperfeiçoada e um processo para a sua preparação
PT100850A (pt) Composicoes farmaceuticas contendo uma mistura sinergica de um agente uricosurico, em especial,de probenecid, com um agente antagonista de aminoacidos excitantes, em especial,um derivado de quinoxalina substituido e sua utilizacao no tratamento de doencas neurodegenerativas
DE69033521T2 (de) Verwendung von arginin als immunstimulator
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
BR0215395A (pt) Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue
BR0011622A (pt) Composto, processo para a preparação de composições aquosas de ácido percarboxìlico, composição aquosa de ácido percarboxìlico, e, uso de uma composição
BR9911274A (pt) Derivados da artemisinina, seus processos de preparação e as composições farmacêuticas que os contêm
BR9916845A (pt) Compostos de (aminoiminometil ouaminometil)benzo-heteroarila substituìdos

Legal Events

Date Code Title Description
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1891 DE 03/04/2007.